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Abstract
TRIM5α from the rhesus macaque (TRIM5αRh) is a restriction factor that shows
strong activity against HIV-1. TRIM5αRh binds specifically to HIV-1 capsid
(CA) through its B30.2/PRYSPRY domain shortly after entry of the virus into
the cytoplasm. Recently, three putative SUMO interacting motifs (SIMs) have
been identified in the PRYSPRY domain of human and macaque TRIM5α.
However, structural modeling of this domain suggested that two of them were
buried in the hydrophobic core of the protein, implying that interaction with
SUMO was implausible, while the third one was not relevant to restriction. In
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identified an additional putative SIM (435VIIC438) which we named SIM4. This
motif is exposed at the surface of the PRYSPRY domain, allowing potential
interactions with SUMO or SUMOylated proteins. Introducing a double
mutation in SIM4 (V435K, I436K) did not alter stability, unlike mutations in
SIM1. SIM4-mutated TRIM5αRh failed to bind HIV-1CA and lost the ability to
restrict this virus. Accordingly, SIM4 undergoes significant variation among
primates and substituting this motif with naturally occurring SIM4 variants
affected HIV-1 restriction by TRIM5αRh, suggesting a direct role in capsid
recognition. Interestingly, SIM4-mutated TRIM5αRh also failed to activate
NF-κB and AP-1-mediated transcription. Although there is no direct evidence
that SIM4 is involved in direct interaction with SUMO or a SUMOylated
protein, mutating this motif strongly reduced co-localization of TRIM5αRh with
SUMO-1 and with PML, a SUMOylated nuclear protein. In conclusion, this new
putative SIM is crucial for both direct interaction with incoming capsids and for
NF-κB/AP-1 signaling. We speculate that the latter function is mediated by
interactions of SIM4 with a SUMOylated protein involved in the NF-κB/AP-1
signaling pathways.
Keywords: Cellular aspects of innate immunity, Proteins, Virology, Viruses, [63_TD$DIFF]
Innate immune system
1. Introduction
Proteins from the TRIM5 family are known for their restriction activity against
retroviruses [1, 2, 3, 4]. Restriction mediated by TRIM5α relies on its ability
to recognize the viral CA core shortly after entry of the virus in the cell, in a
virus-specific and species-specific manner [9_TD$DIFF] 5]. TRIM5α contains RING, B-Box,
coiled-coil (RBCC) domains [6, 7] and the C-terminal SPRY domain (also
called B30.2 or PRYSPRY [10_TD$DIFF] 8]). TRIM5α orthologs differ mostly in the 3
variable regions (V1,V2 and V3) of PRYSPRY [11_TD$DIFF] 9] which confer specificity for
the retroviral CA [12_TD$DIFF] 10]; for instance, HIV-1 is inhibited by rhesus macaque
TRIM5α (TRIM5αRh), but generally not by the human version of the protein [13_TD$DIFF]
[11]. The B-Box and coiled-coil domains are involved in TRIM5αRh
dimerization and higher-order multimerization, properties that are likely
important for the formation of cytoplasmic bodies (CBs) observable by light
microscopy [12, 13, 14]. The RING domain has E3-ubiquitin ligase activity
essential for auto-ubiquitylation of the protein and efficient restriction [14_TD$DIFF] 15].
Interactions between TRIM5α and the retroviral CA N-terminal domain
destabilize the CA lattice [16, 17, 18, 19, 20]. As a result, the CA core
undergoes disassembly and some of its components are degraded, as well as
TRIM5α itself [20, 21, 22]. TRIM5α also impairs viral transport to the nucleus
[23, 24]. Another function has recently been attributed to TRIM5α: the
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activation of innate immunity pathways dependent on AP-1 and NF-κB [25, 26].
The RING domain recruits the E2-ubiquitin conjugating enzyme heterodimer
Ubc13 (Ube2N)/Ube2V2 (Uev2) to generate lysine 63 (K63)-linked
polyubiquitin chains that can be anchored onto TRIM5α through the action of
another E2 enzyme, Ebe2W [15_TD$DIFF] 27]. The presence of K63-linked ubiquitin chains
has been proposed to be important for AP-1 and NF-κB transactivation [26, 28].
Activation of NF-κB and AP-1 by TRIM5α is triggered by contact with a
restriction sensitive virus [16_TD$DIFF] 26] or by transient transfection of TRIM5α [25, 26,
29, 30], but not by stable lentiviral transduction [17_TD$DIFF] 31].
The human genome contains three functional SUMO genes encoding small-
ubiquitin-like modifier (SUMO) -1/2/3 [18_TD$DIFF] 32]. SUMOylation is a post-translational
modification involved in many cellular pathways [32, 33]. SUMO modifies
targeted proteins through its covalent attachment to lysines present in a specific
consensus site: Ψ-K-X-D/E [18_TD$DIFF] 32]. SUMO interacting motifs (SIMs) are necessary
for the non-covalent interaction of proteins with free SUMO [19_TD$DIFF] 34] or with
SUMOylated proteins [20_TD$DIFF] 35] and consist of a short domain rich in hydrophobic
residues [21_TD$DIFF] 34]. TRIM5α proteins have a consensus SUMOylation site at a
position immediately upstream of the RING domain and three putative motifs in
the PRYSPRY domain were proposed to function as SIMs (SIM1, SIM2 and
SIM3) [22_TD$DIFF] 36]. Although TRIM5α was recently found to be SUMOylated [23_TD$DIFF] 37], the
contribution of SUMO to TRIM5α functions has been controversial.
Nonetheless, recent publications have proposed a role for SUMO-1 in retroviral
TRIM5α-mediated restriction [36, 37, 38]. The predicted SUMOylated lysine
present in TRIM5αRh promotes AP-1 and NF-κB signaling pathways through
modulation of the RING domain activity [24_TD$DIFF] 30]. Moreover, it has been recently
found that mutating the putative SIM1 and SIM2 impairs TRIM5α-mediated
NF-κB activation and retroviral restriction, while mutating SIMs had no
significant effect [36, 38, 39]. However, structural data revealed that the
phenotypes of SIM1 and SIM2 mutants were probably a consequence of
PRYSPRY misfolding. Indeed, these motifs appear to be buried deep inside the
hydrophobic core of the PRYSPRY domain, making interactions with other
proteins unlikely [25_TD$DIFF] 39], although it cannot be excluded that contact with CA
might result in structural changes that expose SIM1 and SIM2. In light of these
results, we re-analyzed the PRYSPRY sequence for the presence of other
possible SIMs and uncovered a novel putative SIM which we named SIM4.
Unlike putative SIMs 1 and 2, SIM4 residues are present at the surface of the
protein, making this motif more suitable for interaction with other proteins. Here
we demonstrate the importance of this motif in HIV-1 restriction and in the
activation of NF-κB and AP-1. We propose that this signaling function is
achieved by mediating interactions with an unidentified SUMOylated protein.
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2. Results
2.1. Identification of a new putative SUMO interacting motif
in TRIM5αRh
New insights into TRIM5αRh PRYSPRY structure suggested that the previously
proposed SIMs 1 and 2 were located inside the hydrophobic core of this
domain, implying that direct interactions with SUMO (or any other protein)
were unlikely [26_TD$DIFF] 39]. Analysis of the TRIM5αRh PRYSPRY domain using a
SUMO-binding motif prediction software (GPS-SUMO [27_TD$DIFF] 40]) yielded several
putative SUMO interacting motifs with different scores (Fig. 1A). SIM1
(376ILGV379), SIM2 (405VIGL408) and SIM3 (430IVPL433) were confirmed as
possible SIMs for TRIM5αRh, but the analysis revealed the presence of another
putative SIM (435VIIC438) which we named SIM4. Unlike SIM1 and SIM2,
SIM4 residues are mostly exposed at the surface of the protein, next to SIM3
and within the variable region 3 (V3) (Fig. 1B, C). The side chain of Val435
is not oriented toward the solvent, but the variable regions are present as
flexible loops, and thus this residue is potentially available for protein-protein
interactions.
To investigate the potential role of SIM4 in TRIM5αRh-mediated HIV-1
restriction, the two first aminoacids were mutated to lysines, thus mimicking the
[(Fig._1)TD$FIG]
Fig. 1. Putative SUMO interacting motifs in TRIM5αRh. (A) Table showing scores of predicted
SIMs (shown in red) and their position within TRIM5αRh. (B) Schematic of the full-length
TRIM5αRh protein depicting its main domains and the position of predicted SIMs. V1-V3, variable
regions 1-3. (C) Structural model of the TRIM5αRh PRYSPRY domain (PDB 2ML3) showing the
positions of SIM1 (blue), SIM3 (red) and SIM4 (orange). The localization of V1, V2 and V3
regions is also shown (D) Table showing mutations introduced in TRIM5αRh SIMs.
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mutations that had been introduced in the other putative SIMs (Fig. 1D). The
mutants of putative SIMs 1 and 3 described by others [36, 38, 39] were also
included in this study, while SIM2 was not included since its phenotype was
identical to that of SIM1 [36, 38, 39].
2.2. V435K-I436K TRIM5αRh does not bind HIV-1CA and
does not restrict HIV-1
To analyze the ability of SIM4-mutated TRIM5αRh to restrict HIV-1, CRFK
cells stably expressing WT, SIM1 mutant I376K-L377K, SIM2 mutant
I430K-V431K or SIM4 mutant V435K-I436K TRIM5αRh were challenged with
increasing amounts of VSV G-pseudotyped HIV-1-GFP. Cells transduced with
the empty vector were used as a non-restrictive control. As expected [38, 39],
both WT and I430K-V431K TRIM5αRh strongly restricted HIV-1, by up
to ∼100-fold, while cells expressing I376K-L377K TRIM5αRh were about as
much permissive to HIV-1 infection as cells expressing the empty vector
(Fig. 2A). Expression of V435K-I436K TRIM5αRh resulted in a very small
decrease in HIV-1 permissiveness (less than 2-fold), showing that the ability of
this TRIM5αRh mutant to restrict HIV-1 was almost completely lost (Fig. 2A).
Levels of protein expression were similar for all mutants, except for
I376K-L377K whose expression level was decreased (Fig. 2B), as previously
seen by others [38, 39]. Therefore, the V435K-I436K mutation affects
restriction of incoming HIV-1 seemingly without altering protein levels, unlike
I376K-L377K which reduces both.
We investigated the ability of WT and V435K-I436K TRIM5αRh to physically
interact with HIV-1CA-NC complexes in a CA-binding assay in vitro [41, 42].
Briefly, purified and assembled HIV-1CA-NC complexes were mixed with
TRIM5αRh proteins, which were over-expressed in and isolated from HEK293T
cells. The mixture was then applied to a 70% sucrose cushion and following
centrifugation, pellets and supernatants were analyzed by Western blotting. In
this assay, binding of TRIM5αRh to HIV-1CA is evidenced when both are
present in the pellet fraction. This analysis had previously been conducted for
I376K-L377K and I430K-V431K TRIM5αRh, and results obtained were
consistent with their restriction phenotype since I430K-V431K was found to
bind HIV-1CA-NC complexes while I376K-L377K did not [26_TD$DIFF] 39]. Similarly to
I376K-L377K, V435K-I436K TRIM5αRh failed to bind HIV-1CA-NC
complexes (Fig. 2C), hence explaining its inability to restrict this virus.
HIV-1 restriction by TRIM5α correlates with co-localization of both proteins
following infection, suggesting the existence of a “sequestration” mechanism of
restriction [28_TD$DIFF] 23]. To investigate TRIM5α-CA interactions in a cellular context,
we assessed the co-localization of FLAG-tagged WT, I376K-L377K or
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[(Fig._2)TD$FIG]
Fig. 2. The V435K-I436K mutation in SIM4 suppresses binding of TRIM5αRh to HIV-1CA and
abolishes HIV-1 restriction. (A) Functional restriction assay. CRFK cells stably expressing WT
TRIM5αRh or the various indicated mutants, or transduced with the “empty” vector were challenged
with increasing amounts of VSV G-pseudotyped HIV-1-GFP. Infections were performed in
triplicates and the percentage of cells expressing GFP was analyzed by FACS two days later.
Standard deviation bars are shown. (B) TRIM5αRh expression levels. WT and mutant TRIM5αRh
proteins expression levels in stably transduced CRFK cells were determined by Western blotting
with an anti-FLAG antibody. Actin expression was analyzed as a loading control. (C) CA-binding
assay. HIV-1CA-NC complexes were assembled in vitro and a binding assay was then performed
using FLAG-tagged WT or V435K-I436K TRIM5αRh expressed in HEK293T cells. Lysates from the
transfected HEK293T cells were incubated with HIV-1CA-NC complexes, then the mixtures were
Article No~e00056
6 http://dx.doi.org/10.1016/j.heliyon.2015.e00056
2405-8440/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
V435K-I436K TRIM5αRh with incoming HIV-1CA. Cells were infected with
VSV G-pseudotyped HIV-1-GFP for 2 h and then stained with antibodies
against FLAG and CA. MG132 was used as a proteasome inhibitor to prevent
the degradation of TRIM5αRh [29_TD$DIFF] 22]. Fig. 2D shows representative photographs;
in this assay, CA foci observed likely are single viruses [30_TD$DIFF] 43], but the assay does
not distinguish between fused and unfused particles. WT, I376K-L377K and
V435K-I436K TRIM5αRh were all able to form cytoplasmic bodies (CBs).
Ammonium chloride (NH4Cl) treatment was used as a no-entry control as it
inhibits the acidification of endosomes [31_TD$DIFF] 44], thus preventing the release of
VSV G-pseudotyped viruses in the cytoplasm and making TRIM5α-CA
co-localization improbable. CA foci were bigger when cells were treated with
NH4Cl (Fig. 2D), probably a consequence of CA accumulation in endosomes.
As expected [32_TD$DIFF] 23], a significant fraction (14%) of HIV-1CA foci co-localized
with WT TRIM5αRh CBs (Fig. 2D). In contrast, I376K-L377K and
V435K-I436K TRIM5αRh showed very little co-localization with HIV-1CA
(0.6% and 0.7%, respectively). CA-TRIM5αRh co-localization dropped to 0.1%
when cells were treated with NH4Cl, suggesting that the co-localization events
observed in absence of this drug were specific and involved post-entry virus
cores. Taken together, these results show that mutating SIM4 can disrupt
physical interactions of TRIM5αRh with its viral CA target, hence impairing
restriction.
2.3. V435K-I436K TRIM5αRh is stable and able to shuttle to
the nucleus
As shown in Fig. 2B, I376K-L377K but not V435K-I436K altered steady-state
levels of TRIM5αRh, suggesting that protein folding was affected by the former
but not the latter mutation. To further investigate protein stability, CRFK cells
stably expressing WT, I376K-L377K, I430K-V431K or V435K-I436K
TRIM5αRh were treated with the translation inhibitor cycloheximide (CHX) and
applied to a 70% sucrose cushion and centrifuged. “Input” shows a Western blot analysis of
pre-centrifugation lysates using a FLAG antibody, while “Pellet” shows post-centrifugation pellets
analyzed using antibodies against FLAG or CA. A single experiment representative of three
independent experiments is presented. (D) TRIM5α association with incoming HIV-1CA in cells.
CRFK cells stably expressing WT, I376K-L377K (SIM1 mutant) or V435K-I436K (SIM4 mutant)
TRIM5αRh-FLAG were infected for 2 h with HIV-1-GFP. A rabbit polyclonal anti-FLAG antibody
was used for the detection of TRIM5αRh (red) while HIV-1CA was stained using a mouse
monoclonal antibody (green). DNA was stained using Hoeschst33342 (blue). Examples of co-
localization between WT TRIM5αRh cytoplasmic bodies and HIV-1CA foci are magnified in white
boxes. A quantitative analysis of co-localization frequency was performed and is shown in the graph
on the right. Each bar represents the mean % of co-localization observed in 15 randomly chosen
fields, each field considered as a replicate for statistical analysis. P values were calculated using the
one-way ANOVA test. The total number of CA foci in the 15 fields is shown on top of each bar.
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reduction in protein levels was then monitored over time by Western blotting
coupled with densitometry analysis. As shown in Fig. 3A, the I376K-L377K
TRIM5αRh half-life was <1.5 h, compared to >5 h for WT, I430K-V431K and
V435K-I436K TRIM5αRh. Of note, other studies reported a shorter half-life for
WT TRIM5αRh than in our assay [15, 22], but they used different cell lines.
The rate of decay for a given protein can vary depending on the cell type used
and growth conditions [45, 46]. Using a two-way ANOVA followed by
Dunnett's multiple comparison test, we found no statistically significant
differences for I430K-V431K and V435K-I436K when compared to WT
TRIM5αRh in this assay (P values = 0.8832 and 0.3038, respectively). On the
other hand, I376K-L377K stability was significantly decreased (P < 0.0001),
supporting the misfolding hypothesis.
TRIM5α has the capacity to shuttle between the nucleus and the cytoplasm, and
the fraction of the protein present in the nucleus can be enriched by treatment
with the CRM-1/exportin 1 inhibitor leptomycin B (LMB) [39, 47, 48]. In the
presence of this drug, TRIM5αRh forms nuclear bodies (NBs) that co-localize
with promyelocytic leukemia (PML) bodies [33_TD$DIFF] 47]. CRFK cells transduced with
I376K-L377K, V435K-I436K or WT TRIM5αRh were treated with LMB for
12 h and the presence of TRIM5αRh NBs was analyzed (Fig. 3B). In absence of
the drug, WT, V435K-I436K and I376K-L377K TRIM5αRh formed CBs but not
NBs, as expected [34_TD$DIFF] 1]. I376K-L377K TRIM5αRh CBs were similar to their WT
counterpart, unlike V435K-I436K TRIM5αRh CBs which were noticeably bigger
(a 78.8% increase in diameter as averaged from 150 randomly chosen CBs).
In presence of LMB, WT TRIM5αRh could be found in both cytoplasmic and
nuclear compartments as expected (Fig. 3B). I376K-L377K TRIM5αRh was not
observed in the nucleus, as previously reported [26_TD$DIFF] 39]. Interestingly, the
distribution of V435K-I436K was similar to that of the WT protein, showing
that mutating this motif did not affect nuclear translocation (Fig. 3B).
The relatively large size of V435K-I436K TRIM5αRh CBs (Fig. 3B) prompted
us to analyze the potential of this mutant to multimerize. CRFK cells stably
expressing WT or V435K-I436K TRIM5αRh were lysed and the lysates were
treated with increasing concentrations of glutaraldehyde, a crosslinking agent
previously used in similar experiments [49, 50]. As shown in Fig. 3C, in the
absence of glutaraldehyde we observed only monomers of TRIM5αRh-FLAG
(approximately 54 kDa). Multimers of V435K-I436K TRIM5αRh were present
in greater relative amounts, regardless of the glutaraldehyde concentration used,
compared to the WT (Fig. 3C). This suggests that this mutation increases
TRIM5αRh multimerization potential, explaining the enlarged CBs. Altogether,
the results shown in Fig. 2 and Fig. 3 suggest that V435K-I436K disrupts
restriction by affecting surface determinants of interaction with CA, although we
cannot exclude that its effects on multimerization patterns also play a role.
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[(Fig._3)TD$FIG]
Fig. 3. Characterization of V435K-I436K TRIM5αRh stability, nuclear shuttling and multimerization.
(A) CRFK cells stably expressing WT, I376K-L377K (SIM1 mutant), I430K-V431K (SIM3 mutant)
or V435K-I436K (SIM4 mutant) TRIM5αRh were treated with cycloheximide and protein lysates
were then prepared at the indicated time points. The graph shows mean values of relative protein
densities from two independent experiments normalized to actin at different time points following
cycloheximide treatment, and then normalized to the value obtained at T0. Error bars are shown.
Western blots from one experiment are presented below the graph. (B) IF microscopy analysis of
subcellular distribution. CRFK cells stably expressing FLAG-tagged WT, I376K-L377K,
V435K-I436K TRIM5αRh and empty vector-transduced cells were treated with leptomycin B (LMB)
for 12 h or left untreated prior to fixation and staining with an anti-FLAG antibody (red). DNA was
stained using Hoeschst33342 (blue). Representative images from multiple fields analyzed are shown.
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In contrast, I376K-L377K probably caused major misfolding of the PRYSPRY
domain as also proposed by others [26_TD$DIFF] 39].
2.4. V435K-I436K abolishes the ability of TRIM5αRh to
activate AP-1 and NF-κB
TRIM5α is a pattern recognition receptor that promotes the activation of innate
immune signaling pathways dependent on transcription factors AP-1 and NF-κB
[25, 26, 29, 30]. These innate immune pathways result in the production of
various inflammatory cytokines and chemokines [35_TD$DIFF] 51]. A previous study
proposed that specific interactions between TRIM5 proteins and HIV-1CA lead
to the activation of AP-1 and NF-κB [36_TD$DIFF] 26]. However, TRIM5αRh can also
activate both NF-κB and AP-1 when it is transiently transfected and in the
absence of infection [25, 29, 30, 38]. To determine whether the mutations in the
various putative SIMs could interfere with this TRIM5αRh function, HEK293T
cells were co-transfected with increasing amounts of WT, I376K-L377K,
I430K-V431K or V435K-I436K TRIM5αRh, and a constant concentration of a
plasmid expressing luciferase under control of the NF-κB response element [37_TD$DIFF] 25].
The TRIM5αRh RING domain mutant C35A, which has no ubiquitin ligase
activity and is unable to activate NF-κB, was used as a negative control [37_TD$DIFF] 25].
Another control consisted of cells co-transfected with WT TRIM5αRh and a
version of the luciferase expression plasmid bearing a deletion in the NF-κB
response element. As shown in Fig. 4A, transfection of 3 μg of WT and
I430K-V431K TRIM5αRh resulted in strong NF-κB activation (∼17-fold and
∼16-fold compared to the empty vector control, respectively; P < 0.0001).
Transfection of 1 μg of these plasmids had similar effects, but using smaller
amounts (0.1–0.3 μg) activated NF-κB only weakly (Fig. 4A), as seen
previously [24_TD$DIFF] 30]. C35A and I376K-L377K TRIM5αRh were unable to activate
NF-κB, as recently described by others [38_TD$DIFF] 38]. Interestingly, V435K-I436K
TRIM5αRh did not induce significant NF-κB activation since levels of luciferase
expression were similar to those of the C35A control and the empty vector
control (Fig. 4A). Levels of luciferase expression in cells transfected with 3 μg
of I376K-L377K and V435K-I436K TRIM5αRh were significantly decreased
(C) Multimerization assay. Lysates were prepared from CRFK cells stably expressing FLAG-tagged
WT or V435K-I436K TRIM5αRh. The soluble fraction of each lysate was divided in aliquots that
were treated with different glutaraldehyde concentrations (0, 0.25, 0.5, 1.25 and 2.5 mM) before
performing Western blots using an anti-FLAG antibody. A single experiment representative of three
independent experiments is presented. High molecular weight (HMW) bands correspond to apparent
TRIM5αRh multimers according to the size of the bands. The graph on the right shows the average
(from three experiments) of relative HMW protein density (ranging from 120 to >250 kDa)
calculated at each glutaraldehyde concentration. Standard deviation bars are shown on the graph and
the P value was calculated using a two-way ANOVA statistical test. * points to a non-relevant band
detected by the antibody used.
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compared to cells transfected with the WT plasmid (∼65-fold for I376K-L377K
and ∼11-fold for V435K-I436K TRIM5αRh; P < 0.0001). Levels of TRIM5α
expression were similar for the WT and the various mutants, with the exception
of I376K-L377K which showed reduced expression levels (Fig. 4B). Therefore,
[(Fig._4)TD$FIG]
Fig. 4. The V435K-I436K mutation in SIM4 affects TRIM5αRh-mediated activation of NF-κB and
AP-1. (A) HEK293T cells were transfected with increasing amounts of either WT or the indicated
mutants of pMIP-TRIM5αRh and co-transfected with a constant amount (0.6 μg) of a reporter
plasmid expressing luciferase from a NF-κB-dependent promoter. As controls, cells were
co-transfected with the empty pMIP plasmid and the NF-κB reporter construct, or were co-
transfected with WT TRIM5αRh and the activation-deficient mutant of the reporter construct
(ΔNF-κB-Luc). Two days later, cells were lysed and luciferase activity was measured. Bars show
averages from triplicate transfections with standard deviations. P values obtained when comparing
each of the TRIM5α to the empty vector (1 or 3 μg transfected) were calculated using a two-way
ANOVA test followed by a Tukey's multiple comparisons test: ****<0.0001; ns, non-significant.
(B) The cellular lysates prepared to quantify luciferase activity in (A) were also used to analyze
TRIM5α expression. For this, the three lysates from each triplicate transfection were pooled and
analyzed by Western blotting using an anti-FLAG antibody. Samples were loaded on more than one
gel due to space limitations but all gels and blotting membranes were handled at the same time and
in the exact same way. (C) Same as (A), using a reporter plasmid expressing luciferase from an
AP-1-dependent promoter. Two different DNA amounts (1 and 3 μg) of the different pMIP plasmids
expressing WT, I376K-L377K, I430K-V431K or V435K-I436K TRIM5αRh were co-transfected with
a constant amount of AP-1-Luc (0.6 μg). The empty vector was used as a negative control. The
graph shows relative luciferase activity 48 h post transfection. The experiment was performed in
triplicate and standard deviations are shown. P values obtained when comparing each of the
TRIM5α to the empty vector were calculated using a two-way ANOVA test followed by the Tukey's
multiple comparisons test: **<0.01; ***<0.001; ****<0.0001. (D) TRIM5α protein expression was
analyzed as described in (B).
Article No~e00056
11 http://dx.doi.org/10.1016/j.heliyon.2015.e00056
2405-8440/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
the inability of V435K-I436K TRIM5αRh to activate NF-κB was not caused by
decreased expression levels. On the other hand, I376K-L377K TRIM5αRh low
expression levels partly explain the very low levels of NF-κB induction for this
mutant (Fig. 4A). However, higher protein amounts were observed when 3 μg
of I376K-L377K TRIM5αRh were transfected than when 0.3 μg of either WT or
I430K-V431K TRIM5αRh were used (Fig. 4B), while NF-κB activation was
readily detected for WT and I430K-V431K but not for I376K-L377K
TRIM5αRh in these same conditions (Fig. 4A). Thus, we conclude that both
I376K-L377K and V435K-I436K mutants are deficient for NF-κB activation.
To evaluate the effects of mutating the TRIM5αRh SIMs on AP-1-dependent
transactivation, HEK293T cells were co-transfected with 1 or 3 μg of WT,
I376K-L377K, I430K-V431K or V435K-I436K TRIM5αRh and with 0.6 μg of
a reporter plasmid expressing luciferase under the control of the AP-1 response
element [36_TD$DIFF] 26]. WT and I430K-V431K TRIM5αRh significantly activated AP-1 at
both DNA concentrations compared to the empty vector control (Fig. 4C). On
the other hand, I376K-L377K and V435K-I436K TRIM5αRh were very weak
activators of AP-1, as evidenced by low luciferase signal in both cases.
Specifically, when 3 μg of the TRIM5αRh-expressing plasmid were used, WT
and I430K-V431K TRIM5αRh increased luciferase activity by ∼21-fold and
∼9-fold relative to the empty vector control, respectively (P < 0.0001) while
I376K-L377K and V435K-I436K TRIM5αRh increased it by only ∼2.3-fold
(P = 0.1957) and ∼2.2-fold (P = 0.2304), respectively. Thus, these two mutants
did not activate AP-1 to significant levels, while they resulted in a very
significant (P < 0.0001) decrease in activation levels when compared to the WT
(Fig. 4C). Levels of protein expression were determined in the transfected cells
by Western blot analysis (Fig. 4D) and we found that V435K-I436K TRIM5αRh
was expressed at WT-like levels while I430K-V431K TRIM5αRh was expressed
at smaller levels (a 2- to 3-fold decrease). This explains that in the experiment
shown in Fig. 4C, AP-1 activation by I430K-V431K TRIM5αRh is similarly
less efficient than for the WT control. On the other hand, the inability of
I376K-L377K and V435K-I436K to activate AP-1 does not result from poor
expression levels in HEK293T cells. Altogether, we conclude that V435K-I436K
TRIM5αRh is unable to activate both AP-1 and NF-κB signaling pathways,
suggesting that this motif is a determinant for innate immune signaling.
2.5. Mutating putative SIMs does not hinder the capacity of
TRIM5αRh to trigger K63-linked polyubiquitin chains
formation
E3 ubiquitin ligase activity associated with the RING domain is essential for the
ability of TRIM5α to promote formation of K63-linked ubiquitin chains [26, 52]
that can then mediate the activation of AP-1 and NF-κB signaling through
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phosphorylation of TAK1 [51, 53, 54]. To study the ability of I376K-L377K,
I430K-V431K and V435K-I436K mutants to generate Ub-K63 chains,
FLAG-tagged TRIM5αRh, WT or mutated, was transfected in HEK293T cells
along with a construct expressing ubiquitin. To detect K63-linked polyubiquitin,
Western blot analysis was performed using an antibody specific for this type of
ubiquitin chains [39_TD$DIFF] 55] (Fig. 5A). As controls, cells were co-transfected with
KO-Ubiquitin, a polyubiquitylation-deficient version of ubiquitin in which all
potentially ubiquitylated lysines have been substituted to arginines [40_TD$DIFF] 56].
K63-linked ubiquitin chains were detected between ∼70 and 300 kDa, consistent
with previous reports [26, 30], and such polyubiquitylation products were
almost undetectable in cells transfected with the KO ubiquitin mutant (Fig. 5A).
The C35A TRIM5αRh RING domain mutant was used as a negative control. As
expected, K63-linked ubiquitin chains were almost undetectable in cells
transfected with this mutant (Fig. 5A). Co-transfection of WT, I376K-L377K,
I430K-V431K and V435K-I436K TRIM5αRh with WT ubiquitin resulted in
strong stimulation of K63-linked polyubiquitylation, compared to cells
co-transfected with TRIM5αRh and KO ubiquitin or compared to cells
co-transfected with the empty vector and WT ubiquitin (Fig. 5A, B). A
densitometry-based quantitative analysis was performed using Western blots
from 3 independent experiments (Fig. 5B). Values were obtained by normalizing
relative K63-linked ubiquitin chains densities from the indicated TRIM5αRh
to the one obtained with the empty vector control (CTL) when co-transfected
with WT ubiquitin. The mean levels of TRIM5α protein expression in the
3 experiments were similar for all FLAG-tagged proteins utilized (data not
shown). Results show that only C35A TRIM5αRh was unable to significantly
induce K63-linked ubiquitin chains (P = 0.916 when compared to the empty
vector). In contrast, WT, I376K-L377K, I430K-V431K and V435K-I436K
TRIM5αRh all promoted the formation of K63-linked ubiquitin chains at WT
levels (Fig. 5B). Specifically, all three SIM mutants showed statistically
significant induction of K63-linked polyubiquitin when compared to the empty
control while none of them showed statistically significant differences with the
WT (Fig. 5B). Therefore, the putative SIMs 1 and 4 are dispensable for the
formation of K63-linked ubiquitin chains even though they are required for
NF-κB and AP-1 activation.
2.6. V435K-I436K TRIM5αRh shows reduced co-localization
with PML and SUMO-1 in the nucleus
PML/TRIM19, a member of the TRIM family of proteins, is the main
determinant for the formation of PML bodies, nuclear structures that can harbor
multiple proteins and have known roles in antiviral defense [41_TD$DIFF] 57]. PML is
heavily SUMOylated and SUMO is a major contributing factor to the formation
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[(Fig._5)TD$FIG]
Fig. 5. Mutating putative PRYSPRY SIMs does not affect TRIM5αRh ability to trigger K63-linked
ubiquitin chains formation. (A) HEK293T cells were transfected with either the empty pMIP (CTL)
or with pMIP expressing FLAG-tagged WT, I376K-L377K (SIM1 mutant), I430K-V431K (SIM3
mutant) or V435K-I436K (SIM4 mutant) TRIM5αRh, and co-transfected with WT or KO ubiquitin.
KO ubiquitin has all its lysines mutated to arginine to prevent polyubiquitylation. C35A TRIM5αRh
was used as a negative control for its incapacity to significantly promote K63-linked chains
formation. Two days later, whole cell lysates were analyzed by Western blotting using rabbit
antibodies directed at K63-linked ubiquitin chains or FLAG. A single experiment representative of
three independent experiments is presented. * points to a non-relevant band detected by the antibody
used. Samples were loaded on two gels due to space limitations but gels and blotting membranes
were handled at the same time and in the exact same way. (B) Mean densities of bands ranging
from 75 to >250 kDa detected using the K63 chains-specific antibody, normalized to the control
consisting of cells co-transfected with WT-Ub and empty pMIP. Data were obtained in three
independent experiments and standard deviations are shown. P values were calculated using a
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of PML NBs [42_TD$DIFF] 58]. TRIM5αRh is able to shuttle to the nucleus and co-localize
with PML NBs [33_TD$DIFF] 47]. We hypothesized that direct interactions between SIM4
and either SUMO or a SUMOylated protein may determine the localization of
TRIM5α at PML NBs. Thus, we reasoned that mutating SIM4 would affect the
co-localization of TRIM5α with PML or SUMO or both. To test this possibility,
IF microscopy was performed on CRFK cells stably expressing WT or
V435K-I436K TRIM5αRh and in the presence or absence of LMB. As shown in
Fig. 6A, LMB treatment resulted in a fraction of WT and V435K-I436K
TRIM5αRh being present in the nucleus, while no nuclear TRIM5α staining was
observed in the absence of the drug, as expected [33_TD$DIFF] 47]. A significant fraction of
TRIM5αRh NBs co-localized with SUMO-1 (left panel) and PML (right panel)
in LMB-treated cells, and this was observed for both WT and V435K-I436K
TRIM5αRh. However, co-localization between V435K-I436K TRIM5αRh NBs
and both SUMO-1 and PML was less frequent than for WT TRIM5αRh NBs.
Specifically, an analysis of multiple randomly selected fields (Fig. 6B) showed
that in presence of LMB, 38.6% of WT TRIM5αRh NBs but only 12.9% of
V435K-I436K TRIM5αRh NBs co-localized with SUMO-1 (P < 0.0001).
Similarly, 17.6% of WT TRIM5αRh NBs but only 6.7% of V435K-I436K
TRIM5αRh NBs co-localized with PML (P < 0.0001). Therefore, mutating
putative SIM4 affects TRIM5αRh association with SUMO-1 and PML NBs,
suggesting that this motif is a determinant for the interaction with SUMO or a
SUMOylated protein.
2.7. Natural simian variants of SIM4 activate both NF-KB and
AP-1 signaling pathways and exhibit partial HIV-1 restriction
Our results suggest that SIM4 (435VIIC438) is an important motif for the ability
of TRIM5αRh to inhibit HIV-1 and activate NF-κB/AP-1. We wondered whether
this motif was well conserved among primates given that TRIM5α is known
to have evolved under positive selection in order to restrict different retroviruses
[43_TD$DIFF] 59]. For this purpose, we aligned the TRIM5α coding sequence from
36 primate species. The relationship between these species is shown in Fig. 7.
None of the New World monkeys (NWM) or the prosimians encode an intact
VIIC motif. On the other hand, all representatives of the great apes (human,
chimpanzee, West African chimpanzee, bonobo, gorilla, Sumatran orangutan and
Bornean orangutan) and a majority of the Old World monkeys (OWM) have
conserved SIM4 VIIC motifs. Based on these observations, we propose that
SIM4 VIIC did not appear independently in these two groups but, instead, arose
before the split of Old World monkeys and hominoids which occurred
approximately 29 million years ago. Within the OWM and hominoids lineages,
SIM4 has been mutated at 5 independent times throughout evolution (stars on
branches in Fig. 7). Analysis of TRIM5α exon 8 sequences from 34 individual
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crab-eating macaques was done using BLAST and revealed 2 individuals from
the Mauritian population which encode VIVC. For rhesus macaque, sequences
from 15 individuals were analyzed and one individual from Guangsi was found
[(Fig._6)TD$FIG]
Fig. 6. Decreased nuclear co-localization of V435K-I436K TRIM5αRh with endogenous SUMO-1
and PML. (A) CRFK cells stably expressing FLAG-tagged WT or V435K-I436K (SIM4 mutant)
TRIM5αRh were treated or not with LMB for 12 h and then processed for IF microscopy. A rabbit
anti-FLAG antibody was used for the detection of TRIM5αRh (red) and mouse antibodies were used
for the detection of endogenous SUMO-1 and PML (green). DNA was stained with Hoechst33342
(blue). White arrows point to examples of co-localizations of nuclear TRIM5αRh with SUMO-1 (left
panels) or PML (right panels). (B) Quantitative analysis of the frequency of WT or V435K-I436K
TRIM5αRh NBs co-localization with either SUMO-1 (left panel) or PML (right panel) in
LMB-treated cells. The percentage of WT and V435K-I436K TRIM5αRh NBs co-localizing with
SUMO-1 or PML is shown. Each bar represents the average % of co-localization observed in
15 randomly chosen fields considered as replicates. P values were calculated using the Student
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to encode VTIC. These data demonstrate that SIM4 is quite variable both
between and within primate species.
All natural SIM4 variants were tested for their ability to activate NF-κB/AP-1
and restrict HIV-1. Using mutagenesis, we substituted TRIM5αRh-SIM4 (VIIC)
with all the natural variants (VKIC, VNIC, VTIC, VIVC, VIFC and MTIC),
resulting in the production of 6 new proteins. First, their capacity to activate the
[(Fig._7)TD$FIG]
Fig. 7. Divergence of the TRIM5α putative SIM4 motif during [3_TD$DIFF]primate speciation. The SIM4 motif
was analyzed in 36 primate species (bases 1291-1302 of the TRIM5 gene, encoding residues
431-434 in the human TRIM5α protein). These primate species represent ∼87 million years of
primate evolution and the four major primate groups are shown. Amino acid residues encoded in
this motif by each primate genome are indicated. Ancestral forms of the SIM4 motif were predicted
with the Program PAML [4_TD$DIFF] 79]. Asterisks indicate positions where mutations in this motif are
predicted to have occurred. The gray box indicates the clade of primates whose ancestral SIM4
motif is VIIC. SNPs within the SIM4 domain have been reported in both rhesus and crab-eating
macaque populations (M. mulatta from Guangxi province and individuals from the Mauritian
M. fascicularis population, respectively) [70,71]. These polymorphisms are indicated on the tree
with hyphens, illustrating the alternate alleles that are co-circulating. Underlined names indicate
primates that live in Continental Africa.
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NF-κB and AP-1 signaling pathways was tested, as described above, using
co-transfections in HEK293T cells. All the SIM4 variants were able to activate
NF-κB (Fig. 8A) and AP-1 (Fig. 8B) since significant luciferase activity was
observed in both experiments. The SIM4 variants seemed to show some level of
reduction (∼15% to 60%) in their capacity to activate both pathways, compared
to the WT, but this could largely be attributed to decreased expression levels
(Fig. 8C, D). In contrast, V435K-I436K TRIM5αRh was unable to activate both
signaling pathways, as expected. Taken together, these results suggest that,
despite the emergence of variations within the SIM4 sequence among primates,
its capacity to activate NF-κB and AP-1 is conserved.
The second function to be analyzed was TRIM5α capacity to inhibit HIV-1
infection. CRFK cells stably expressing all the SIM4 variants, V435K-I436K or
WT TRIM5αRh were challenged with increasing amounts of HIV-1-GFP and
further analyzed by flow cytometry. As expected, WT TRIM5αRh strongly
inhibited HIV-1 (Fig. 8E) and V435K-I436K TRIM5αRh failed to restrict HIV-1
and was only slightly less permissive than cells expressing the empty vector
control. All the SIM4 variants restricted HIV-1 at an intermediate level: ∼8-fold
less than WT and ∼6-fold more than the empty vector control, on average.
Levels of protein expression were determined by Western blotting and were
found to be comparable in all transduced cells (Fig. 8E). An upper unspecific
band was detected by the anti-FLAG antibody, as previously observed in CRFK
cells (Fig. 3C). Thus, mutating VIIC into naturally occurring sequences found in
other species affects TRIM5αRh ability to optimally restrict HIV-1, consistent
with this motif being involved in interactions with CA in addition to being
important for NF-κB/AP-1 signaling. The fact that, for some of the mutants
tested, the effect on NF-κB activation is much milder than the effect on
restriction supports a model in which the two functions can have distinct
determinants.
3. Discussion
In this study, we identified a new putative SIM (435VIIC438) in TRIM5αRh
PRYSPRY that is, on one hand, involved in specific interactions with the
retroviral capsid, and on the other hand, is also essential for the activation of
NF-κB/AP-1 at least in the infection-free model employed here. Mutating this
motif impaired restriction (Fig. 2) and NF-κB/AP-1 signaling (Fig. 4), while a
similar mutation in the adjacent SIM3 (430IVPL433) affected neither function. As
also proposed by Brandariz-Nuñez et al. [25_TD$DIFF] 39], our results support the hypothesis
that mutating the previously proposed SIM1 causes gross misfolding of the
PRYSPRY domain, preventing the nuclear translocation of TRIM5αRh (Fig. 3)
and resulting in its proteasomal degradation (Nepveu-Traversy and Berthoux,
unpublished data). Misfolded proteins are generally degraded by the
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[(Fig._8)TD$FIG]
Fig. 8. Natural simian variants of SIM4 activate both NF-KB and AP-1. (A) HEK293T cells were
co-transfected with either WT or the indicated mutants of pMIP-TRIM5αRh (2 μg) and a reporter
plasmid expressing luciferase from a NF-κB-dependent promoter (0.6 μg). As controls, cells
were co-transfected with the empty pMIP plasmid and the NF-κB reporter construct, or were
co-transfected with WT TRIM5αRh and the activation-deficient mutant of the reporter construct
(ΔNF-κB-Luc). Cells were lysed 48 h post transfection and luciferase activity was measured. Bars
show averages from triplicate transfections with standard deviations. (B) Similar experiment using
a reporter plasmid expressing luciferase from an AP-1-dependent promoter. The empty vector was
used as a negative control. The graph shows relative luciferase activity 48 h post transfection. The
experiment was performed in triplicate and standard deviations are shown. (C) The cellular lysates
prepared to quantify luciferase activity in (A) were also used to analyze TRIM5αRh expression. For
this, the three lysates from each triplicate transfection were pooled and analyzed by Western blotting
using an anti-FLAG antibody. (D) TRIM5αRh expression levels in cells from the experiment shown
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ubiquitin-proteasome system to ensure cellular homeostasis [44_TD$DIFF] 46]. Although the
SIM1 mutant (I376K-L377K) did not show an unstable phenotype upon
transfection in HEK293T cells (see Fig. 4, Fig. 5), this is probably due to over-
expression conditions in this particular cell line. In contrast to I376K-L377K, the
SIM4 mutant (V435K-I436K) was stable and able to shuttle to the nucleus (Fig. 3)
indicating that this mutant was probably not misfolded, consistent with SIM4 being
mostly a surface motif. However, V435K-I436K TRIM5αRh shows increased
potential for multimerization and CB formation (Fig. 3). The TRIM5α coiled-coil
and Linker2 domains upstream of SPRY form an anti-parallel homodimer which is
expected to bring the SPRY domains in relatively close proximity [60, 61], and it is
conceivable that mutations in the proposed SIM4 could modulate interactions
between the two PRYSPRY domains with negative consequences on restriction. In
addition, it is possible that the larger size of the SIM4-mutated TRIM5α CBs
means that less TRIM5α is available to intercept incoming HIV-1, contributing to
the loss of restriction.
The CA protein of the N-tropic murine leukemia virus (N-MLV), which is
restricted by human TRIM5α (TRIM5αHu) [45_TD$DIFF] 11] is likely modified by SUMO-1 [46_TD$DIFF]
[62]. It has been proposed that TRIM5αHu restricts N-MLV efficiently through
the binding of TRIM5αHu SIM1 and/or SIM2 to the incoming SUMOylated
N-MLV CA [22_TD$DIFF] 36]. Recent structural data suggesting that SIM1 and SIM2 are
internal motifs [47_TD$DIFF] 39] seem to invalidate this theory, although other structural data
indicate that the PRYSPRY domain can adopt several conformations [48_TD$DIFF] 63] and
that the variable loops at its surface probably undergo conformational changes
upon binding to CA [49_TD$DIFF] 64], opening the possibility that SIM1 or SIM2 could be
brought at the surface of the protein upon CA interactions. This, however, does
not appear to be a likely possibility. The putative SIM identified here, SIM4, is
clearly a surface motif and thus could potentially bind a SUMOylated CA.
However, HIV-1CA has not been found to be SUMOylated, and in addition, the
evidence linking SUMO to direct restriction of incoming retroviruses is not
overwhelming. Arriagada and colleagues showed that over-expression of
SUMO-1 in 293T cells restricts N-MLV and only in conditions in which this
virus is also restricted by TRIM5αHu [50_TD$DIFF] 36], suggesting that SUMO is a co-factor
for TRIM5α. However, over-expression of SUMO-1 had much smaller effects
on the permissiveness of other human cell lines to N-MLV infection, and a
in (B). The analysis was done as in (C). (E) The HIV-1 restriction activity of all TRIM5αRh SIM4
variant constructs was assessed by infecting CRFK cells stably expressing the indicated TRIM5αRh
with increasing amount of HIV-1-GFP. Percentages of GFP-positive cells were measured by FACS
two days later. The experiment was performed in triplicate and standard deviation bars are shown.
WT and mutant TRIM5αRh protein expression levels in stably transduced CRFK cells were
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follow-up study focusing this time on TRIM5αRh did not show that over-
expression of SUMO-1 inhibited HIV-1 in restrictive conditions [38_TD$DIFF] 38]. Instead,
the authors reported that SUMO-1 depletion canceled HIV-1 restriction by
TRIM5αRh, but this conclusion was weakened by inefficient SUMO-1
knockdown and abnormally low levels of HIV-1 restriction by TRIM5αRh in the
control cells [38_TD$DIFF] 38]. Similarly, another recent study reported a reduction in
restriction by transfection of siRNAs targeting SUMO-1, Ubc9 or PIAS1 [51_TD$DIFF] 37].
However, restriction of HIV-1 by TRIM5αRh in this transient transfection-based
setting was similarly much weaker than in stably transduced cells (less than
4-fold compared to the usual ∼100-fold). A more recent study reported that
perturbing the SUMOylation pathway by over-expression of Gam1 [65, 66] had
no impact on the restriction of N-MLV in human cells [25_TD$DIFF] 39], and we found that
Gam1 does not influence the restriction of HIV-1 by TRIM5αRh expressed in
human cells (Nepveu-Traversy and Berthoux, unpublished data). Thus, there is
altogether neither strong nor even consensual evidence that the SUMOylation
pathway is important for the direct restriction of incoming retroviruses,
especially for HIV-1. On the other hand, the presence of a conserved putative
SUMOylation site and of SIMs indicates a role for SUMO in TRIM5α
functions, and we propose that SUMO and the SUMOylation pathway are
involved in the activation of NF-κB/AP-1 by TRIM5α. Recently, we have
shown that mutating the putatively SUMOylated lysine (lysine 10) reduces the
capacity of TRIM5αRh to generate K63-linked polyubiquitin and to activate
NF-κB and AP-1 [24_TD$DIFF] 30]. Here we show that the SIM4 double substitution mutant
V435K-I436K completely disrupts the NF-κB/AP-1 activation potential of
TRIM5αRh, while mutating SIM3 has no effect (Fig. 4).
It has been previously suggested that activation of NF-κB and AP-1 by TRIM5α
is the consequence of a signaling cascade that includes the formation of
K63-linked ubiquitin chains. Similarly to TRAF6, a RING domain protein,
TRIM5α recruits a E2 heterodimer, Ubc13/Ube2V2 [52_TD$DIFF] 27], to catalyze the
formation of K63-linked ubiquitin chains [16_TD$DIFF] 26] which are important for the
activation of TAK1 [53_TD$DIFF] 52], a key factor for the downstream activation of both
NF-κB and AP-1 [54_TD$DIFF] 53]. Interestingly, all the PRYSPRY mutants tested in this
study were able to trigger significant formation of K63-linked ubiquitin chains
(Fig. 5). This result suggests that the various putative SIMs, and probably the
PRYSPRY domain itself, are irrelevant to this function, at least in this over-
expression experimental model. This conclusion is also supported by the fact
that the SIM1 mutant can promote K63-linked ubiquitin despite its PRYSPRY
domain being possibly misfolded. In contrast, mutating the RING zinc finger
abolished this function (Fig. 5), confirming that this domain is an essential
determinant for the generation of K63-linked ubiquitin by TRIM5α [36_TD$DIFF] 26].
Moreover, the fact that mutations in the putative SIM1 and SIM4 motifs abolish
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the stimulation of NF-κB and AP-1 indicates that presence of K63-linked
polyubiquitin chains is not the sole requirement for activation of these innate
immunity pathways. Thus, the SIM4 (435VIIC438) motif seems to be a
determinant for an as yet unidentified activation step that is required for
activation of NF-κB and AP-1 pathways. We cannot exclude, however, that the
K63-linked ubiquitin chains generated by V435K-I436K TRIM5αRh are
defective in a way that could not be revealed by our Western blot analysis, or
that they are not properly located in the cell to activate the NF-κB and AP-1
pathways. A direct role for SIM4 in activating NF-κB and AP-1 appears more
likely, however, and we propose that SIM4 interacts with SUMO or an
unidentified SUMOylated protein and that this interaction contributes to the
activation of NF-κB/AP-1. The existence of such interactions was suggested by
IF microscopy results (Fig. 6).
The exact nature of the involvement of SUMO and the SUMOylation pathway
in the activation of NF-κB/AP-1 by TRIM5α remains an open question. TAK-1
binding protein 2 (TAB2) was recently proposed to be SUMOylated, and
mutating its SUMOylated lysine enhanced the activity of TAB2 and resulted in
increased AP-1 activation [55_TD$DIFF] 67]. Also, NF-κB essential modulator (NEMO/IKKγ)
is SUMOylated in response to various stress signals, allowing NF-κB activation
by translocation of SUMOylated NEMO to the nucleus [56_TD$DIFF] 68]. On the other hand,
the inhibitor of NF-κB (IκBα), which hides the nuclear localization signal, is
degraded by the proteasome to allow translocation of NF-κB to the nucleus, but
SUMOylation stabilizes it and consequently inhibits NF-κB activation [57_TD$DIFF] 69].
Taken together, these findings show that activation of NF-κB is extensively
controlled by SUMOylation, providing several speculative models for TRIM5α
interacting with a SUMOylated factor in order to promote innate immune
activation. For instance, TRIM5α could interact, through the SIM4 motif, with
SUMOylated IκBα to disrupt its interaction with NF-κB and thus promote
NF-κB translocation to the nucleus. It is possible that the shuttling of TRIM5α
in the nucleus and its transient association with PML bodies are important in its
capacity to activate NF-κB and AP-1.
A phylogenetic analysis of the proposed SIM4 revealed some significant
changes in some of the 36 primates analyzed (Fig. 7). Six naturally occurring
variants were tested for their ability to restrict HIV-1 when placed in a
TRIM5αRh context and all were less efficient than their WT counterpart in this
assay (Fig. 7E), confirming that this motif is important for CA interactions in
addition to being important for the activation of NF-κB/AP-1. Interestingly,
intra-species polymorphism was found at this position in rhesus and crab-eating
macaques. The analysis of NCBI TRIM5α sequences from 34 crab-eating
macaques revealed 2 isolates bearing the motif VIVC, and 1 of 15 rhesus
macaques had the motif VTIC. These species are already known for their
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polymorphism due to the occasional presence of a supplementary allele coding
for TRIMCyp [70, 71]. Interestingly, individuals expressing the modified SIM4
(VIVC and VTIC) did not have the additional TRIMCyp allele. It is possible
that TRIMCyp and SIM4 variants emerged in response to different viruses. The
high level of polymorphism in SIM4 also supports a role for this motif in
interacting with incoming retroviral CA cores. Of note, the VIIC motif is found
in great apes and in OWM, the two primate groups living in Africa where one
finds the most cases of SIV infections. It is possible that primates in other parts
of the world do not undergo a strong selective pressure in order to make
TRIM5α ultra-responsive towards lentiviruses. Interestingly, the ability to
activate NF-κB and AP-1 was maintained for the six naturally occurring SIM4
variants tested here (Fig. 7), suggesting that this function is essential and is
evolutionarily conserved despite variations in the sequence that affect the
capacity of these variants to restrict HIV-1 (Fig. 8). This observation supports
the idea that the two functions are not necessarily coupled, even though
interaction of TRIM5α with restriction sensitive viruses was shown to activate
NF-κB/AP-1 [36_TD$DIFF] 26].
In conclusion, we have characterized a new putative SIM (435VIIC438) in
TRIM5αRh that is important for TRIM5α-dependent innate immune signaling,
possibly through its capacity to interact with SUMO or a SUMOylated protein,
and which also has a role in the retroviral tropism of TRIM5α.
4. Materials and methods
4.1. Plasmid DNAs and mutagenesis
pMIP-TRIM5αRh expresses a C-terminal FLAG-tagged version of TRIM5αRh
and has been described before [72, 73]. We designed the following primers to






TCGTGTTG-3′ (forward) and 5′-CAACACGATCAGGACAAA-
TCTTCTTAGAGAG
GGGCACAATGAAAG-3′ (reverse). SIM4 variants were constructed using
pMIP-TRIM5αRh as template and mutations were introduced using the following
primers: VKIC, 5′-GTGCCCCTCTCTGTGAAAATTTGTCCTGA-















GGGGCACAATGAAAG-3′ (reverse); MTIC, 5′-GTGCCCCT-
CTCTATGACTATTTGTCCTGATCGTGTTG-3′ (forward) and
5′-GATCAGGACAAATAGTCATAGAGAGGGGCACAATGAAAG-3′
(reverse). All mutations were confirmed by Sanger sequencing. The vector
production plasmids pMD-G, pΔR8.9, pCL-Eco and pTRIP-CMV-GFP have
all been extensively described elsewhere [44, 74, 75, 76). pRK5-HA-
Ubiquitin WT and KO [58_TD$DIFF] 56] were obtained from Ted Dawson (Johns Hopkins
University, Baltimore, MD) through Addgene. The KO ubiquitin version of
this plasmid bears the following mutations eliminating all possibilities of
ubiquitin chain formation: K6R, K11R, K27R, K29R, K33R, K48R and
K63R. pCEP4-NF-κB-Luc expresses luciferase under the control of an
NF-κB-dependent promoter, while pCEP4-ΔNF-κB-Luc is transcriptionally
deficient due to deletion of the NF-κB binding site [37_TD$DIFF] 25]. Both constructs
were kind gifts from M. Emerman (University of Washington, Seattle, WA).
pHTS-AP1-Luc expresses luciferase under the control of an AP-1-dependent
promoter and was a kind gift from J. Luban (University of Massachusetts
Medical School, Worcester, MA).
4.2. Cell lines
Human embryonic kidney (HEK) 293T cells and Crandell-Rees feline kidney
(CRFK) cells were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal bovine serum and antibiotics at 37 °C,
5% CO2. All cell culture reagents were from HyClone (Thermo Scientific,
Logan, UT, USA).
4.3. Transfections and virus production
MLV and HIV-1-based vectors were produced through transient transfection
of HEK293T cells using polyethylenimine (MW 25,000; Polysciences,
Warrington, PA) and collected as previously described [72, 77]. To produce
the MLV-based MIP vectors, cells were transfected with the relevant pMIP
plasmid and co-transfected with pCL-Eco and pMD-G. All stably transduced
cell lines were produced as previously described [72, 77]. Successfully
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transduced CRFK cells were selected with 4 μg/ml of puromycin. To
produce the GFP-expressing HIV-1 vector HIV-1TRIP-CMV-GFP (nicknamed
HIV-1-GFP), cells were co-transfected with pΔR8.9, pMD-G and
pTRIP-CMV-GFP.
4.4. Viral challenges
CRFK cells were plated in 24-well plates at 30,000 cells per well and infected
the next day with different amounts of HIV-1-GFP or using a defined
multiplicity of infection (MOI). Two days post-infection, cells were trypsinized
and fixed in 2% formaldehyde in a PBS solution. The % of GFP-positive cells
was then determined by analyzing 10,000 cells using a FC500 MPL cytometer
with the CXP software (Beckman Coulter).
4.5. Western blotting
Cells were lysed in RIPA buffer (150 mM NaCl, 1% Triton, 0.1% SDS,
50 mM Tris pH 8.0, 0.5% sodium deoxycholate and Complete protease
inhibitor cocktail (Roche, Bale, Switzerland). Whole cell lysates were then
boiled in protein sample buffer (60 mM Tris-HCl pH 6.8, 10% glycerol,
0.002% bromophenol blue, 2% SDS, 2% beta-mercaptoethanol) and resolved by
SDS-PAGE. After transfer to nitrocellulose membranes, blots were probed with
rabbit anti-FLAG (1:2000, Cell Signaling, Danvers, Massachusetts) followed
by a secondary antibody coupled to horseradish peroxydase (Santa Cruz,
Dallas, TX), or with a HRP-conjugated mouse anti-actin (1:20,000, EMD
Millipore, Billerica, MA), and revealed using a chemiluminescence detection
system (SuperSignal West Femto, Thermo Scientific, Waltham, MA). Images
were recorded on a UVP (Upland, California) EC3 imaging system, and
densitometry analyses were performed using the area density tool of the
VisionWorks LS software (UVP).
4.6. Stability assay
CRFK cells expressing TRIM5αRh were plated in 6-well plates at a cell
density leading to 80% confluent cells on the next day. Cells were then
treated with 100 μM cycloheximide (Sigma, Saint Louis, MO) and harvested
at different time points as previously described [14_TD$DIFF] 15]. Cells were lysed in
stability lysis buffer [NaCl 100 mM, NP-40 0.5%, SDS 0.1%, Tris 100 mM
(pH 8.0) and Complete protease inhibitor cocktail (Roche, Bale, Switzerland)]
and further processed for Western blotting. Protein density was measured
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4.7. Multimerization assay
CRFK cells stably expressing either FLAG-tagged WT or V435K-I436K
TRIM5αRh were plated in three 10-cm plates at a cell density leading to 80%
confluent cells on the next day. Cells from the 3 dishes were then pooled
together and lysed with 0.05% NP-40 on ice for 15 min. After centrifugation,
supernatants were divided in 5 aliquots and treated for 5 min with different
glutaraldehyde (J.T. Baker, Phillipsburg, NJ) concentrations (0, 0.25, 0.5,
1.25, 2.5 mM). Tris-HCl 0.1 M pH 7.5 was added to stop reaction and all
samples were denaturated and further processed for Western blotting as
described above.
4.8. NF-κB and AP-1 reporter assays
HEK293T cells were plated in 12-well plates at a cell density leading to 80%
confluent cells at the time of transfection and were then transfected with
increasing amounts (0.1, 0.3, 1 and 3 μg) of FLAG-TRIM5α-expressing
pMIP-TRIM5α supplemented with empty pMIP to reach a total of 3 μg, or
transfected with fixed amount (2 μg) of FLAG-tagged WT or mutant TRIM5α.
Cells were simultaneously transfected with 0.6 μg of pCEP4-NF-κB-Luc,
pCEP4-ΔNF-κB-Luc or pHTS-AP1. Cells were lysed with RIPA buffer 48 h
post-transfection and assessed for luciferase activity using the BrightGlow
Luciferase kit (Promega). Luminescence was measured with a Synergy HT
multi-detection microplate reader (BioTek, Winooski, VT) and analyzed using
the Gen5 software (BioTek).
4.9. K63 ubiquitin chains formation assay
HEK293T cells were seeded in 12-well plates at a cell density leading to 80%
confluency. On the next day, cells were co-transfected with either WT or mutant
FLAG-tagged TRIM5α (2 μg) and either WT or KO pRK5-HA-ubiquitin
(0.5 μg). The “empty” plasmid pMIP was used as a negative control. Cells were
lysed in RIPA buffer 48 h post-transfection and processed for Western blotting.
A monoclonal human/rabbit chimeric K63-linked ubiquitin chains-specific
antibody (clone Apu, Millipore) was used (1:1000 dilution) to detect K63
ubiquitin chains.
4.10. Immunofluorescence (IF) microscopy
60,000 CRFK cells were plated on microscope glass coverslips (Fisherbrand) in
6-well plates. Treatments with the nuclear export inhibitor leptomycin B (LMB,
Enzo LifeScience) were done at 20 ng/ml for 12 h prior to fixation. For the
experiment involving HIV-1 infection, cells were treated with MG132 (1 μg/ml)
for 6 h and infected with HIV-1-GFP (MOI of 4) for 2 h prior to fixation.
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Control infections were done in presence of ammonium chloride (NH4Cl,
20 mM, Sigma). Cells were washed with PBS, fixed for 10 min in 4%
formaldehyde-PBS at 37 °C, washed three times in PBS and permeabilized with
0.1% Triton X-100 for 2 min on ice. Cells were then washed twice with PBS
and treated with 10% normal goat serum (Vector laboratories) in PBS for
30 min at room temperature. This saturation step was followed by a 4 h
incubation with a rabbit polyclonal FLAG antibody (Cell Signaling) and an
antibody against endogenous SUMO-1 (mouse monoclonal antibody,
Invitrogen), both at a 1:200 dilution in PBS with 10% normal goat serum. To
stain endogenous promyelocytic leukemia protein (PML), primary mouse
monoclonal antibody (Enzo Life Sciences, Farmingdale, NY) was used at a
1:50 dilution. HIV-1CA was stained using a mouse monoclonal anti CAp24
antibody purified in our laboratory from the 183 hybridoma clone, AIDS
Research and reference Reagent Program, NIAID, NIH. Fluorescent staining
was done by incubating with an Alexa594-conjugated goat anti-rabbit antibody
and an Alexa488-conjugated goat anti-mouse antibody (each used at 1:200
dilution). Cells were washed 4 times in PBS before mounting in Vectashield
(Vector Laboratories, Burlington, Ontario). Hoechst33342 (0.8 μg/ml; Molecular
Probes) was added along with the penultimate PBS wash to reveal DNA.
Pictures were generated using a Zeiss AxioObserver microscope equipped with
an Apotome module and the Axiovision software. Imaging parameters were set
to identical values across samples.
4.11. Binding of TRIM5αRh to HIV-1 capsid-nucleocapsid
(CA-NC) complexes
HIV-1CA-NC was expressed and purified as previously described [39, 41] and
further used for the binding assay. HEK293T cells were transfected with
plasmids expressing either WT or V435K-I436K FLAG-tagged TRIM5αRh.
Two days post transfection, cells were lysed as previously described [26_TD$DIFF] 39].
CA-NC complexes assembled in vitro were incubated with cell lysates for 1 h
at room temperature. The mixture was then applied to a 70% sucrose cushion
and centrifuged at 100,000 g for 1 h at 4 °C. Following centrifugation, the
supernatant was removed and pellet was resuspended in protein sample
buffer. Western blotting was performed to detect TRIM5αRh (anti-FLAG
antibody, Cell Signaling) and HIV-1CA-NC (anti-CAp24 antibody,
Immunodiagnostics).
4.12. Phylogenetic analysis
Primate gene sequences for TRIM5 were obtained from GenBank. TRIM5 exon
8 was sequenced from 5 additional primate species (bonobo, pileated gibbon,
agile gibbon, yellow-cheeked gibbon and black mangabey). Primary and
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immortalized primate cell lines were grown and genomic DNA was harvested
(detailed description of cell lines can be found in Demogines et al. [59_TD$DIFF][1_TD$DIFF] 78]).
TRIM5 sequence was amplified by PCR using the following primer pairs:
5′-CTCCTTCCAAGACACACATAACTTACCC-3′ with
5′-AAGAGGTGCTGTACAGAAGGGGC-3′. The PCR fragments were then
sequenced using the PCR primers listed above or the following primers:
5′-GCTACTGGGTTATA
GGGTTAGAGGAAGG-3′ or 5′-CTCCTTATAACTTCTAAACAAGG-
TTCCTCCC-3′. Primate TRIM5 exon 8 gene sequences have been deposited in
GenBank (accession numbers: KJ701422-KJ701426).
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